Lomitapide: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) and TLV (Sweden) recommended or restricted lomitapide, while AOTMIT (Poland), AWMSG (Wales) and NYE METODER (Norway) did not recommend it.
Assessment has run over 11.8 years, from 6 Dec 2013 at AWMSG (Wales) to 28 Oct 2025 at TLV (Sweden).
CIPM (Spain) changed its position: not recommended on 26 Sep 2024, recommended by 23 Oct 2024, after a resubmission.
No assessment is on file from PBAC (Australia) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
Not every gap is a refusal: for lomitapide, 1 submission was never made — an outcome set by the company rather than the assessor.
The file is active: 4 of 10 records date from 2023 or later.
Against its own class, lomitapide is an outlier: 43% of its decisive outcomes were positive, where molecules sharing ATC class C10A average 68%.
AWMSG (Wales) was first to assess lomitapide, on 6 Dec 2013; TLV (Sweden) did not open a file until 28 Oct 2025 — an unusually long tail of 11.8 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 6 years in total.
CIPM (Spain) is the only agency to have returned to lomitapide, recording 2 separate entries.
9 of the 18 agencies in this archive hold a record for lomitapide.
The full ledger for lomitapide reads 4 not recommended, 3 recommended, 1 no benefit and 1 advice, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 1 Jun 2025 | Som supplement til en fettfattig diett og andre lipidsenkende legemidler, med eller uten LDL aferese hos voksne med homo… | not introduced | source |
| CIPM (Spain) | 23 Oct 2024 | Indicaciones terapéuticas autorizadas: Lojuxta está indicado como complemento a una dieta baja en grasas y a otros medic… | financed by the SNS, on appeal · art. 92 a, c | source |
| AOTMIT (Poland) | 15 Nov 2022 | programu lekowego „Leczenie homozygotycznej hipercholesterolemii rodzinnej u dorosłych (ICD-10 E78.01) | not recommended | source |
| G-BA (Germany) | 27 Nov 2015 | Lojuxta — benefit assessment §35a | added benefit: not proven | source |
| ZIN (Netherlands) | 23 Mar 2015 | GVS-advies lomitapide (Lojuxta®) bij homozygote familiaire hypercholesterolemie (HoFH) | advice published (GVS) | source |
5 further decisions for lomitapide, across 5 agencies, are not shown here. They include the most recent record on file, 28 Oct 2025 from TLV (Sweden); its outcome is in the subscriber dataset. They link to 5 further source documents.
Related molecules
- evolocumab — same ATC class C10A — Lipid modifying agents
- alirocumab — same ATC class C10A — Lipid modifying agents
- rosuvastatin — same ATC class C10A — Lipid modifying agents
- inclisiran — same ATC class C10A — Lipid modifying agents
- evinacumab — same ATC class C10A — Lipid modifying agents
- ezetimibe — same ATC class C10A — Lipid modifying agents
Coverage: 10 decisions for lomitapide from 9 agencies, 2013 to 2025. Data to 7 Sep 2026. ATC class C10A — Lipid modifying agents. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.